90834 Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 

• P–AKT–S473 expression in Figure 

3C in Genes Cancer 2014 and lanes 1– 

4 of DEPTOR expression in Figure 3C of 

Cancer Res. 2016 with resizing. 

• Lanes 7–9 of p70S6K1 expression in 

Figure 1A of Genes Cancer 2014 and 

DEPTOR expression in Figure 4C of 

Cancer Res. 2016. 

• STAT3 associated kinase activity in 

Figure 4A and lanes 1–4 of p110 mu 

associated kinase activity in Figure 5B 

of Oncogene 2004. 

• Lanes 7–8 of ACTIN expression in 

Figure 1A and lanes 7–8 of ACTIN 

expression in Figure 1C of PLoS One 

2014. 

• Lanes 3–4 of P–MNK and T–MNK 

expression in Figure 1C of PloS One 

2014 and lanes 1–2 of FKHD–P and 

FKHD–T expression (top panels) in 

Figure 1B of Mol Cancer Ther. 2005. 

• Lanes 4–8 of P–AKT (S473) and 

actin expression in Figure 2A of Mol 

Cancer Ther. 2011 and AKT and S6K 

expression in Figure 1F of PloS One 

2017 with a 180 degree rotation of the 

P–AKT/AKT panels. 

• Lanes 1–2 of T–HSP27 expression 

and lanes 4–5 of GAPDH expression in 

Figure 2B of Oncogene 2013. 

• Lanes 1–3 of p–erk and lanes 2–4 of 

t-erk expression in Figure 3B and lanes 

1–3 of erk(T202/Y204) and erk 

expression in Figure 4A of J Biol Chem. 

2012. 

• a-tubulin expression in Figure 4D 

and 4E of Genes Cancer 2014. 

• C-myc expression in Figure 1B and 

lanes 1–4 of T-p70 expression in Figure 

1E of Oncogene 2016. 

• T–4E–BP1 (a, b and g 

phosphorylated forms) expression 

(middle panel) and lanes 1–4 of T–4E– 

BP (a, b and g phosphorylated forms) 

expression (right panel) of 

Supplemental Figure 2A of Oncogene 

2016. 

• T–S6 expression and C–myc 

expression in Figure 1F of Oncogene 

2016. 

• Lanes 2–5 of MNK–P and MNK–T 

expression (left panel) in Figure 3A and 

ERK–T and Hsp–27–T expression in 

Figure 4A of Oncogene 2016. 

• MNK1, MNK2 and GAPDH 

expression in Figure 3E of Oncogene 

2016 and MNK1, MNK2 and GAPDH 

expression in Figure 3A of PloS One 

2014. 

• ire–1–total expression (right panel) 

in Figure 5B of Mol Cancer Res. 2016 

and mTor expression in Figure 8A of 

Genes Cancer 2014 with resizing. 

• The right panel of ACTIN 

expression in Figure 2A and the right 

panel of ACTIN expression in Figure 2g 

of Mol Cancer Ther. 2019. 

• Lanes 1–6 of DEPTOR and mTOR 

expression in Figure 1A of Genes 

Cancer 2014 and DEPTOR and mTor 

expression in Figure 6A of Mol Cancer 

Ther. 2019. 

• IRS–1 expression in lanes 4–5 and 

lanes 8–9 in Figure 6B of Mol Cancer 

Ther. 2005. 

• AKT expression (bottom panel) in 

Figure 1Aand lanes 7–9 of IRS–1 

expression in Figure 6B of Mol Cancer 

Ther. 2005. 

• Lanes 4–6 of IGF–R expression and 

lanes 4–6 of FLAG expression in Figure 

5B of Mol Cancer Ther. 2005 with a 180- 

degree rotation. 

• Lanes 2–3 of AKT–T expression 

(4th panel) in and lanes 1–2 of AKT–T 

expression (6th panel) in Figure 1C of 

Mol Cancer Ther. 2005. 

• Lanes 1–2 of AKT–P expression 

(top panel) and lanes 1–2 of AKT–P 

expression (5th panel) in Figure 1E of 

Mol Cancer Ther. 2005. 

• Lanes 1–3 and lanes 5–7 of FKH–T 

expression in Figure 3C of Blood 2003. 

• Lane 1 of p70 expression and 

Ser411 expression in Figure 4B and lane 

4 of Ser411 expression and lanes 1–2 of 

Ser411 expression in Figure 4c of Blood 

2003. 

• Lanes 1 and 3 of ERK–P expression 

and lanes 2 and 4 of ERK–T expression 

in Figure 2C of Blood 2003. 

Based on these findings of research 

misconduct, which the Respondent did 

not appeal, the Department has imposed 

the following corrective actions: 

(1) Prohibition from conducting VA 

research for at least 2 years; 

(2) Notification to the relevant 

journals of the research misconduct 

findings. 

Signing Authority 

Denis McDonough, Secretary of 

Veterans Affairs, signed and approved 

this document on November 12, 2024, 

and authorized the undersigned to sign 

and submit the document to the Office 

of the Federal Register for publication 

electronically as an official document of 

the Department of Veterans Affairs. 

Jeffrey M. Martin, 

Assistant Director, Office of Regulation Policy 

& Management, Office of General Counsel, 

Department of Veterans Affairs. 

[FR Doc. 2024–26756 Filed 11–15–24; 8:45 am] 

BILLING CODE 8320–01–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

[OMB Control No. 2900–0012] 

Agency Information Collection Activity 

Under OMB Review: Application for 

Cash Surrender or Policy Loan and 

Application for Cash Surrender 

(Docusign) 

AGENCY: Veterans Benefits 

Administration, Department of Veterans 

Affairs. 

ACTION: Notice. 

SUMMARY: In compliance with the 

Paperwork Reduction Act (PRA) of 

1995, this notice announces that the 

Veterans Benefits Administration, 

Department of Veterans Affairs, will 

submit the collection of information 

abstracted below to the Office of 

Management and Budget (OMB) for 

review and comment. The PRA 

submission describes the nature of the 

information collection and its expected 

cost and burden, and it includes the 

actual data collection instrument. 

DATES: Comments and 

recommendations for the proposed 

information collection should be sent by 

December 18, 2024. 

ADDRESSES: To submit comments and 

recommendations for the proposed 

information collection, please type the 

following link into your browser: 

www.reginfo.gov/public/do/PRAMain, 

select ‘‘Currently under Review—Open 

for Public Comments’’, then search the 

list for the information collection by 

Title or ‘‘OMB Control No. 2900–0012.’’ 

FOR FURTHER INFORMATION CONTACT: VA 

PRA information: Maribel Aponte, (202) 

461–8900, vacopaperworkreduact@

va.gov. 

SUPPLEMENTARY INFORMATION: 

Title: Application for Cash Surrender 

or Policy Loan (VA Form 29–1546). 

Application for Cash Surrender (VA 

Form 29–1546e—DocuSign). 

OMB Control Number: 2900–0012— 

https://www.reginfo.gov/public/do/ 

PRASearch. 

Type of Review: Extension without 

change of a currently approved 

collection. 

Abstract: The Application for Cash 

Surrender or Policy Loan solicits 

information needed from Veterans to 

apply for cash surrender value or policy 

loan on his/her insurance. The VA Form 

29–1546e has been added to this 

collection. This is an electronic version 

of the 29–1546 but is for cash surrender 

only. This form was created so Veterans 

can apply for a cash surrender of their 

policy online. This will not affect the 

number of respondents but will make it 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 222 / Monday, November 18, 2024 / Notices 90835 

easier and reduce the time it takes for 

Veterans to receive the cash value of 

their policy. The information on this 

form is required by law, 38 U.S.C. 1906 

and 1944, 38 CFR 6.115, 6.116, 6.117, 

8.27, 6.100, 6.101 and 8.28. 

An agency may not conduct or 

sponsor, and a person is not required to 

respond to a collection of information 

unless it displays a currently valid OMB 

control number. The Federal Register 

Notice with a 60-day comment period 

soliciting comments on this collection 

of information was published at 89 FR 

73507, September 10, 2024. 

Affected Public: Individuals or 

Households. 

Estimated Annual Burden: 4,939 

hours. 

Estimated Average Burden per 

Respondent: 10 minutes. 

Frequency of Response: Upon 

Request. 

Estimated Number of Respondents: 

29,636. 

Authority: 44 U.S.C. 3501 et seq. 

Maribel Aponte, 

VA PRA Clearance Officer, Office of 

Enterprise and Integration, Data Governance 

Analytics, Department of Veterans Affairs. 

[FR Doc. 2024–26799 Filed 11–15–24; 8:45 am] 

BILLING CODE 8320–01–P 


lotter on DSK11XQN23PROD with NOTICES1